CRBU Q2 2021 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CRBUCaribou Biosciences, Inc.

$181M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-82.6% YoY

Gross Profit

$1M100.0% margin

Operating Income

-$16M-1081.6% margin

Net Income

-$14M-969.6% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

-6.9%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$17M

Stock-Based Comp.

$593,000

Balance Sheet

Total Assets

$158M

Total Liabilities

$206M

Stockholders' Equity

-$48M

Cash & Equivalents

$130M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$8M	-82.6%
Gross Profit	$1M	$8M	-82.6%
Operating Income	-$16M	-$2M	-607.9%
Net Income	-$14M	-$2M	-664.5%

Geographic Segments

UNITED STATES

$1M93%

Non Us

$111,0007%